References
1. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in
a Long-Term Care Facility in King County, Washington. N Engl J Med 2020.
21;382(21):2005-2011
2. Bailly B, Guilpain L, Bouiller K, et al. BNT162b2 mRNA vaccination
did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly
nursing home but reduced transmission and disease severity. Clin Infect
Dis 2021. 16:ciab446
3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the
BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-15.
4. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of
Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection
Among Nursing Home Residents Before and During Widespread Circulation of
the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety
Network, March 1–August 1, 2021. MMWR Morb Mortal Wkly Rep. ePub: 18
August 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7034e3
5. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity
of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med
2020;383:2439-50.
6. Blain H, Tuaillon E, Gamon L, et al. Spike Antibody Levels of Nursing
Home Residents With or Without Prior COVID-19 3 Weeks After a Single
BNT162b2 Vaccine Dose. JAMA 2021. 15;325(18):1898-1899
7. Blain H, Tuaillon E, Gamon L, et al. Antibody response after one and
two jabs of the BNT162b2 vaccine in nursing home residents: The
CONsort-19 study. Allergy 2021. doi: 10.1111/all.15007
8. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three
Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
N Engl J Med 2021. 12;385(7):661-662
9. Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 Outbreak Associated
with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility
After Vaccination Program - Kentucky, March 2021. MMWR Morb Mortal Wkly
Rep 2021;70:639-43.
10. Canaday DH, Carias L, Oyebanji OA, et al. Reduced BNT162b2 mRNA
vaccine response in SARS-CoV-2-naive nursing home residents. Clin Infect
Dis 2021. May 16:ciab447
11. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2
infections among skilled nursing facility residents and staff members -
Chicago, Illinois, December 2020-March 2021. Am J Transplant
2021;21:2290-7.
12. Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 Variants and
Vaccines. N Engl J Med 2021;385:179-86.
13. McCallum M, Bassi J, De Marco A, et al. SARS-CoV-2 immune evasion by
the B.1.427/B.1.429 variant of concern. Science 2021. 373(6555):648-654
14. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious
SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat
Med 2021;27:917-24.
15. Becker M, Dulovic A, Junker D, et al. Immune response to SARS-CoV-2
variants of concern in vaccinated individuals. Nat Commun 2021;12:3109.
16. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants,
spike mutations and immune escape. Nat Rev Microbiol 2021;19:409-24.
17. Marot S, Malet I, Leducq V, et al. Neutralization heterogeneity of
United Kingdom and South-African SARS-CoV-2 variants in
BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. Clin
Infect Dis 2021. May 29:ciab492
18. Elshazli RM, Toraih EA, Elgaml A, et al. Diagnostic and prognostic
value of hematological and immunological markers in COVID-19 infection:
A meta-analysis of 6320 patients. PLoS One 2020;15:e0238160.
19. Uribarri A, Nunez-Gil IJ, Aparisi A, et al. Impact of renal function
on admission in COVID-19 patients: an analysis of the international HOPE
COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. J
Nephrol 2020;33:737-45.
20. Rolland Y, Benetos A, Villars H, Braun H, Blain H. Editorial: A
COVID-19 Support Platform for Long Term Care Facilities. J Nutr Health
Aging 2020;24:461-2.
21. Blain H, Rolland Y, Tuaillon E, et al. Efficacy of a Test-Retest
Strategy in Residents and Health Care Personnel of a Nursing Home Facing
a COVID-19 Outbreak. J Am Med Dir Assoc 2020;21:933-6.
22. Blain H, Rolland Y, Schols J, et al. August 2020 Interim EuGMS
guidance to prepare European Long-Term Care Facilities for COVID-19. Eur
Geriatr Med 2020;11:899-913.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987;40:373-83.
24. Liotti FM, Menchinelli G, Marchetti S, et al. Evaluation of three
commercial assays for SARS-CoV-2 molecular detection in upper
respiratory tract samples. Eur J Clin Microbiol Infect Dis
2021;40:269-77.
25. Blain H, Rolland Y, Benetos A, et al. Atypical clinical presentation
of COVID-19 infection in residents of a long-term care facility. Eur
Geriatr Med 2020;11:1085-8.
26. Van Praet JT, Vandecasteele S, De Roo A, De Vriese AS, Reynders M.
Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19
Vaccine in nursing home residents. Clin Infect Dis 2021. Apr 7;ciab300
27. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels
are highly predictive of immune protection from symptomatic SARS-CoV-2
infection. Nat Med 2021.
28. Hingrat QL, Visseaux B, Laouenan C, et al. Detection of SARS-CoV-2
N-antigen in blood during acute COVID-19 provides a sensitive new marker
and new testing alternatives. Clin Microbiol Infect 2020.
8;27(5):789.e1-5.
29. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the
first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection
in residents of long-term care facilities in England (VIVALDI): a
prospective cohort study. Lancet Infect Dis 2021. S1473-3099(21)00289-9.
30. McEllistrem MC, Clancy CJ, Buehrle DJ, Lucas A, Decker BK. Single
dose of a mRNA SARS-CoV-2 vaccine is associated with lower
nasopharyngeal viral load among nursing home residents with asymptomatic
COVID-19. Clin Infect Dis 2021. Mar 26:ciab263
31. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is
associated with increased disease severity and mortality. Nat Commun
2020;11:5493.
32. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to
detect SARS-CoV-2 seroconversion in humans. Nat Med 2020;26:1033-6.
33. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2
antibody titers track with functional humoral stability. Nat Commun
2021;12:1018.
34. English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG.
Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay
Including the New Variants of Concern, VOC 202012/V1 (United Kingdom)
and VOC 202012/V2 (South Africa), and First Steps towards Global
Harmonization of COVID-19 Antibody Methods. J Clin Microbiol
2021;59:e0028821.
35. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2
variants B.1.351 and B.1.1.7. Nature 2021;593:130-5.
36. Collier DA, De Marco A, Ferreira I, et al. Sensitivity of SARS-CoV-2
B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 2021;593:136-41.
Bas du formulaire